Sany Group and Fosun contributed to a $61.4m round for the third-party drug development services provider, which counts Jilin Aodong Medicine as an earlier backer.

Tencent and existing investor Nan Fung Life Sciences have helped the ophthalmology drug developer complete its series B round.

Cybrexa has secured $25m to progress a cancer treatment based on research at Yale University and University of Rhode Island.

The nanoemulsion delivery system developer raised series A funding from Haohai Biological alongside an $8m payment for the Chinese rights to its products.

Dell Technologies Capital returned for a round that took the cancer diagnostics technology developer's overall funding to $52m.

Grifols has agreed to buy the remaining 56% of antibody drug developer GigaGen having invested $35m four years ago.

Johnson & Johnson Innovation – JJDC helped the eye drop developer close a series A round that will fund development of lead asset Brimochol.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

UW Madison’s small-molecule therapy spinout has raised $170m in venture funding since emerging from stealth less than a year ago.

Koch Disruptive Technologies has provided $110m for the drug discovery technology startup's series B round following a $190m first close in January.